Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence84
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma72
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events51
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?44
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma44
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma41
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects35
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review32
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence32
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review28
Current status and novel insights into the role of metastasectomy in the era of immunotherapy28
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis25
Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas24
Importance of radiation-related cognitive decline in older adults who receive cranial radiation21
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes21
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan19
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer19
Prognostic factors of undifferentiated embryonal sarcoma of the liver in children: a SEER-based study18
0.15324878692627